Management of Type 2 Diabetes Mellitus

Initial Assessment and Treatment Decision

For newly diagnosed type 2 diabetes patients with high blood sugar levels or poor glucose control, initiate insulin therapy immediately, according to the American Diabetes Association 1, 2
For patients with ketosis, diabetic ketoacidosis, or when distinction between type 1 and type 2 diabetes is unclear, insulin therapy should be started immediately, as recommended by the American Association of Clinical Endocrinologists 1
For all other newly diagnosed type 2 diabetes patients, start metformin as first-line therapy alongside lifestyle modifications, as suggested by the American College of Physicians 1, 2

Monitor HbA1c every 3 months until target is reached, then at least twice yearly, according to the American Diabetes Association 1, 2
Recommend finger-stick blood glucose monitoring for patients who take insulin or medications with hypoglycemia risk, are initiating or changing treatment regimen, have not met treatment goals, or have intercurrent illnesses, as recommended by the Endocrine Society 1

For patients with cardiovascular disease risk factors, consider adding SGLT-2 inhibitor or GLP-1 receptor agonist as second-line therapy, as suggested by the American Heart Association 1
For patients who require third-line therapy, add a third agent from a different class if dual therapy is insufficient, according to the American Association of Clinical Endocrinologists 2
For patients who require fourth-line therapy, consider insulin therapy when triple therapy fails to achieve glycemic targets, as recommended by the American Diabetes Association 2

Implement evidence-based nutrition guidelines focusing on weight management, as recommended by the Academy of Nutrition and Dietetics 1
Prescribe at least 150 minutes per week of moderate-intensity or 75 minutes of vigorous-intensity physical activity for adults, according to the American College of Sports Medicine 1
Limit non-academic screen time to less than 2 hours per day, as suggested by the American Academy of Pediatrics 1

Aggressively manage cardiovascular risk factors, such as hypertension, dyslipidemia, and microalbuminuria, according to the American College of Cardiology 3
For patients with type 2 diabetes and additional ASCVD risk factors, consider SGLT-2 inhibitors or GLP-1 receptor agonists even if glucose control is adequate with metformin, as recommended by the American Heart Association 1